hereditary tyrosinaemia type 1
Metabolic · 2014–2015
2decisions
1medicine
2carried consumer input
42individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nitisinone Treatment of hereditary tyrosinaemia type 1 (HT-1) in patients with confirmed clinical diagnosis based on detection of succinylacetone in urine and/or blood. | Jul 2015 | Not recommended | 18 individuals Metabolic Dietary Disorders Association |
| nitisinone Treatment of hereditary tyrosinaemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. | Nov 2014 | Deferred | 24 individuals |
Who spoke
Metabolic Dietary Disorders Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.